In conclusion, this study identifies nSMase2 as the major neutral N-SMase upregulated in response to doxorubicin, a first-line agent used in the treatment of breast cancer, and suggests that nSMase2 is a primary pathway of ceramide generation in the doxorubicin response. The gene discussed is SMPD3; the disease is breast cancer.